Parkman Healthcare Partners LLC Buys Shares of 104,081 InspireMD, Inc. (NYSE:NSPR)

Parkman Healthcare Partners LLC acquired a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent SEC filing.

Separately, Affiance Financial LLC bought a new stake in shares of InspireMD during the 3rd quarter worth approximately $492,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of InspireMD in a research note on Wednesday. They set a “sell” rating on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Trading Down 1.3 %

NYSE:NSPR opened at $3.01 on Wednesday. The stock has a 50 day simple moving average of $2.60 and a 200 day simple moving average of $2.64. InspireMD, Inc. has a 1-year low of $1.81 and a 1-year high of $3.42. The stock has a market cap of $78.50 million, a P/E ratio of -4.01 and a beta of 0.98.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. During the same period in the prior year, the company posted ($0.15) earnings per share. As a group, sell-side analysts forecast that InspireMD, Inc. will post -0.79 EPS for the current year.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.